Evaluation of the use of contrast agents in medical imaging
DOI:
https://doi.org/10.56294/shp2024103Keywords:
nephropathy, contrast, medical imaging, prevention, safetyAbstract
Advances in medical imaging techniques have significantly improved clinical diagnosis, and contrast agents have become essential tools in procedures such as computed tomography and magnetic resonance imaging. However, their use has been associated with significant risks, particularly contrast-induced nephropathy (CIN), which mainly affects patients with pre-existing renal or cardiovascular disease. The studies reviewed addressed the pathophysiological mechanisms of this complication, as well as the most effective prevention strategies, such as intravenous hydration and the use of agents with lower renal toxicity potential. The safety of iodinated and even gadolinium-based contrast agents was also analysed, highlighting that some compounds offered a safer profile. Despite advances, clinical controversies persisted, and the need for further research to optimise preventive management and ensure patient safety was emphasised.
References
1. Shams E, Mayrovitz HN. Contrast-Induced Nephropathy: A Review of Mechanisms and Risks [Internet]. Cureus; 2021 May 4 [cited 2024 Oct 4]. Available from: https://www.cureus.com/articles/58401-contrast-induced-nephropathy-a-review-of-mechanisms-and-risks
2. Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, Spandidos DA, et al. Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. Pharmacol Ther. 2017 Dec;180:99–112.
3. Contrast Media Safety Committee. ESUR Guidelines on Contrast Agents, version 10.0. European Society of Urogenital Radiology; 2018.
4. Gorelik Y, Yaseen H, Heyman SN, Khamaisi M. Negligible risk of acute renal failure among hospitalized patients after contrast-enhanced imaging with iodinated versus gadolinium-based agents. Invest Radiol. 2019 May;54(5):312–8.
5. McDonald RJ, McDonald JS, Bida JP, Carter RE, Fleming CJ, Misra S, et al. Intravenous contrast material–induced nephropathy. Contrast Media. 2013;267(1).
6. Qian G, Liu C, Guo J, Dong W, Wang J, Chen Y. Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and congestive heart failure. Clin Cardiol. 2019 Jan;42(1):21–5.
7. Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: A meta-analysis of randomized, controlled trials. PLoS One. 2013 Jan 30;8(1):e55124.
8. Weisbord SD, Palevsky PM, Kaufman JS, Wu H, Androsenko M, Ferguson RE, et al. Contrast-associated acute kidney injury and serious adverse outcomes following angiography. J Am Coll Cardiol. 2020 Mar;75(11):1311–20.
9. Cheungpasitporn W, Thongprayoon C, Brabec B, Edmonds P, O′Corragain O, Erickson S. Oral hydration for prevention of contrast-induced acute kidney injury in elective radiological procedures: A systematic review and meta-analysis of randomized controlled trials. N Am J Med Sci. 2014;6(12):618.
10. Lee T, Kim WK, Kim AJ, Ro H, Chang JH, Lee HH, et al. Low-osmolar vs. iso-osmolar contrast media on the risk of contrast-induced acute kidney injury: A propensity score matched study. Front Med. 2022 Apr 29;9:862023.
11. Everson M, Sukcharoen K, Milner Q. Contrast-associated acute kidney injury. BJA Educ. 2020 Dec;20(12):417–23.
12. Van Der Molen AJ, Dekkers IA, Bedioune I, Darmon-Kern E. A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol in more than 57,000 patients: part 1—intravenous administration. Eur Radiol. 2022 Mar 21;32(8):5532–45.
13. Ehrmann S, Quartin A, Hobbs BP, Robert-Edan V, Cely C, Bell C, et al. Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis. Intensive Care Med. 2017 Jun;43(6):785–94.
14. Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, et al. Use of intravenous gadolinium-based contrast media in patients with kidney disease: Consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2021 Jan;298(1):28–35.
15. Honda T, Kuriyama K, Kiso K, Kishimoto K, Tsuboyama T, Inoue A, et al. Incidence rate of severe adverse drug reactions to nonionic contrast media at the National Hospital Organization Osaka National Hospital. Allergo J Int. 2020 Nov;29(7):240–4.
16. Cha MJ, Kang DY, Lee W, Yoon SH, Choi YH, Byun JS, et al. Hypersensitivity reactions to iodinated contrast media: A multicenter study of 196,081 patients. Radiology. 2019 Oct;293(1):117–24.
17. Gomi T, Nagamoto M, Hasegawa M, Katoh A, Sugiyama M, Murata N, et al. Are there any differences in acute adverse reactions among five low-osmolar non-ionic iodinated contrast media? Eur Radiol. 2010 Jul;20(7):1631–5.
Published
Issue
Section
License
Copyright (c) 2024 Aline Aparecida Pacheco , Analía Claudia Sabattini (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
